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Differences in effectiveness and use 
of laparoscopic surgery in locally 
advanced colon cancer patients
M. Schootman1,2*, Matthew Mutch3, T. Loux1, J. M. Eberth4 & N. O. Davidson5,6
Patients with locally advanced colon cancer have worse outcomes. Guidelines of various organizations 
are conflicting about the use of laparoscopic colectomy (LC) in locally advanced colon cancer. We 
determined whether patient outcomes of LC and open colectomy (OC) for locally advanced (T4) colon 
cancer are comparable in all colon cancer patients, T4a versus T4b patients, obese versus non-obese 
patients, and tumors located in the ascending, descending, and transverse colon. We used data from 
the 2013–2015 American College of Surgeons’ National Surgical Quality Improvement Program. 
Patients were diagnosed with nonmetastatic pT4 colon cancer, with or without obstruction, and 
underwent LC (n = 563) or OC (n = 807). We used a composite outcome score (mortality, readmission, 
re-operation, wound infection, bleeding transfusion, and prolonged postoperative ileus); length of 
stay; and length of operation. Patients undergoing LC exhibited a composite outcome score that 
was 9.5% lower (95% CI − 15.4; − 3.5) versus those undergoing OC. LC patients experienced a 11.3% 
reduction in postoperative ileus (95% CI − 16.0; − 6.5) and an average of 2 days shorter length of stay 
(95% CI − 2.9; − 1.0). Patients undergoing LC were in the operating room an average of 13.5 min longer 
(95% CI 1.5; 25.6). We found no evidence for treatment heterogeneity across subgroups (p > 0.05). 
Patients with locally advanced colon cancer who receive LC had better overall outcomes and shorter 
lengths of stay compared with OC patients. LC was equally effective in obese/nonobese patients, in 
T4a/T4b patients, and regardless of the location of the tumor.
Colorectal cancer (CRC) is a leading cause of cancer death with an estimated 95,520 new cases and 50,260 deaths 
in  20171. Laparoscopic colectomy (LC) has gained widespread acceptance for resection of CRC, with better short 
term complication rates and similar long-term outcomes relative to open colectomy (OC) in stage I-III  patients2–4. 
However, about ten percent of patients are diagnosed with locally advanced cancer (T4) with locoregional inva-
sion, who may have worse  outcomes5. Such tumors have a reasonable chance of a cure when accompanied by 
an en bloc multivisceral  resection6–8, but a landmark randomized study excluded locally advanced colon cancer 
when comparing LC versus  OC9.
The safety and effectiveness of LC in T4 colon cancer patients is still unresolved because of technical difficul-
ties with en-bloc dissection of large tumors. The American Society of Colon & Rectal Surgeons recommends that 
“laparoscopic resection of T4 colon cancer may be performed safely and effectively with long-term oncologic 
outcomes that do not differ in comparison with open surgery.”10 In contrast, the National Comprehensive Cancer 
Network guidelines for colon cancer surgery recommend against LC when locally advanced disease is  present11. 
The European Association of Endoscopic Surgery (EAES) also failed to recommend LC in locally advanced colon 
 cancer12. While recent studies have compared LC with OC in locally advanced colon  cancer13–17, many of those 
studies used small sample sizes or studied only patients from single institutions, while others were performed 
outside the United States.
There is also a major need to determine which T4 patients are appropriate candidates for  LC18. For example, 
T4b tumors (invade and/or adhere to other organs or structures) are technically more demanding than T4a 
tumors (penetrate to the surface of the visceral peritoneum), depending on the nature of the multivisceral 
resection required to achieve negative margins. Resection of locally advanced tumors is difficult to perform 
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laparoscopically because of the need to perform an extended resection and obtaining negative margins is more 
 challenging19. The effectiveness of LC versus OC across different locations in locally advanced tumors in the 
colon is unknown. The advantages of LC have prompted its application to a wider range of patients with colon 
cancer such as those who are obese, have locally advanced tumors or require more extended resections. Older 
studies have argued that LC in obese patients is technically more difficult and could be a  contraindication20,21. 
Additionally, observational studies with small patient samples examining transverse colon cancers have found 
that laparoscopic resection resulted in acceptable outcomes, but such studies may have been  underpowered22–24. 
Studies to compare directly the effectiveness of LC versus OC across different locations in locally advanced 
tumors in the colon are not available, and transverse colon cancers were excluded from the landmark Clinical 
Outcomes of Surgical Therapy (COST)  trial9.
We examined differences in 30 day outcomes of LC versus OC and also compared subgroups of patients: 
(1) T4a and T4b patients, (2) those with tumors located in the left, right, or transverse colon, and (3) obese and 
nonobese patients. Our findings should help guide the use of LC in minimally invasive surgery in T4 colon 
cancer patients.
Materials and methods
Data source. Data for our cohort was constructed using the 2013–2015 American College of Surgeons’ 
National Surgical Quality Improvement Program (ACS-NSQIP) Participant Use File and Targeted Colectomy 
File. Preoperative patient comorbidities, preoperative laboratory results, intraoperative procedures, 30-day 
postoperative mortality rates, and complications were abstracted by trained reviewers. Additional details are 
described here (https:// www. facs. org/ quali ty- progr ams/ acs- nsqip). All methods were carried out in accordance 
with relevant guidelines and regulations. The Saint Louis University Institutional Review Board deemed this 
protocol to be exempt from oversight since it was nonhuman subjects research.
Patient selection. All patients who underwent colectomy (with or without obstruction) and were diag-
nosed with pT4 colon cancer (and nonmetastatic disease M0 or Mx) were included. Patients who underwent 
LC, including robotic, or OC were included; patients with other types of surgery were excluded. We included 
patient in the LC groups that resulted in conversion to OC based on intention to  treat13,25. Patients who under-
went emergency surgery were excluded since they are much more likely to receive open  surgery26, which may 
lead to difficulty creating comparable groups of OC and LC patients. To test the robustness of our findings, we 
performed a sensitivity analysis by including LC performed with open or hand assistance in the LC group. Hand 
or open assistance may be used as a bridge between a straight LC and an OC in cases where straight LC may be 
difficult because of the size of tumor, local advancement, or intra-abdominal  adhesions16. There were no partici-
pants who were younger than 18 years of age.
Patient outcomes. Outcomes included operation time, anastomotic leakage, mortality, readmission, re-
operation, length of stay, wound infection, transfusion, prolonged postoperative ileus, sepsis, myocardial infarc-
tion, deep vein thrombosis, and pulmonary embolism. Conversion occurred when LC was converted to an 
unplanned OC. Re-operation was defined as any unplanned return to the operating room for a surgical proce-
dure, for any reason, within 30 days of the colectomy at any hospital or surgical facility. All-cause mortality was 
defined as deaths within 30 days following surgery. Readmission was defined as any readmission (to the same 
or another hospital), for any reason, within 30 days of the colectomy. A wound infection included superficial 
or deep incisional surgical site infection or any other wound infection. Postoperative bleeding occurrence was 
defined as any transfusion given from the start of the colectomy to 72 h post operation. Because of the infre-
quent occurrence for some of the postoperative outcomes, we constructed a composite outcome of mortality, 
readmission, re-operation, wound infection, bleeding occurrence, and prolonged postoperative ileus. Patients 
with at least one adverse outcome were contrasted to those without any such adverse  outcomes27, recognizing 
the variability in the severity of its components but summarizing information across several quality dimensions.
Covariates. Based on previous  studies28,29, we included patient sex, age, Hispanic ethnicity, race, ASA group-
ing, smoking status, chronic comorbid conditions (congestive heart failure, hypertension, chronic obstructive 
pulmonary disease, chronic kidney disease, anemia, weight loss > 10%, bleeding disorder, transfusion), patient 
functional status prior to surgery, chemotherapy, and mechanical bowel preparation.
T4a and T4b colon cancers were determined based on AJCC TNM staging. Tumor location was based on 
post-operative diagnosis using ICD-9 or ICD-10 codes. The patient’s most recent height and weight documented 
in the medical record within the 30 days prior to the colectomy or at the time the patient was being considered a 
candidate for surgery was used to calculate BMI. Patients were classified as obese (BMI ≥ 30 kg/m2) or nonobese 
(BMI < 30 kg/m2).
Statistical analysis. We used 1:1 propensity score matching to obtain patient groups with comparable 
characteristics to assess the effect of LC on patient outcomes with all covariates. We calculated standardized 
differences for all covariates before and after matching. A standardized difference of less than − 0.1 or greater 
than 0.1 was used as a marker for  imbalance30. We also compared the means and variances of the covariates after 
matching to determine the balance between the LC and OC groups. We calculated the average treatment effect 
among the treated (ATT) and associated 95% confidence intervals to describe the effectiveness of LC versus OC, 
focusing on absolute differences.
To assess potential heterogeneous treatment effects of LC by T4 type, we first matched patients who received 
LC to those who received OC. Matching was done in a 2:1 ratio using optimal matching on the propensity score, 
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e(x), with a caliper of 0.25 × sd(e[x])31. Once patients were matched, we ran separate regressions in the LC and 
OC groups to predict respective outcomes. The coefficients for T4 type were compared between the two models 
to assess treatment heterogeneity due to these  factors32. A similar approach was used to assess treatment hetero-
geneity due to tumor location (left, right, transverse) and obesity.
We conducted sensitivity analyses to challenge the robustness of the findings. We examined the ATT using 
inverse probability weighting and nearest neighbor propensity score matching. P < 0.05 was considered to be 
statistically significant.
Results
Patients. Data were collected on 29,922 patients with colectomies for colon cancer with or without obstruc-
tion (any stage) in the 2013–2015 NSQIP data with ASA class < 5. Of those, 1370 patients were diagnosed with 
locally advanced colon cancer (T4) non-emergently with ASA class 0-IV, 563 patients underwent LC and 807 
patients underwent OC, and these together comprised the study population (Table 1). Patients were predomi-
nantly white (71.1%) and non-Hispanic (84.0%). Twenty-nine percent of patients were obese. Most patients had 
ASA class three (56.0%), and were nonsmokers (82.1%).
Unmatched outcomes. Of all patients, 45.1% experienced at least one adverse postoperative outcome 
(Table 2), which was higher in OC (52.2%) versus LC patients (35.0%) (p < 0.05). Mortality was 3.1%, which was 
higher in OC (4.1%) versus LC patients (1.8%) (p < 0.05). Ileus was prolonged in OC patients (26.9%) versus LC 
patients (14.4%) (p < 0.05). Blood transfusions were more frequent in OC (22.2%) versus LC patients (11.9%) 
(p < 0.05). Length of stay was an average of 3 days shorter for LC versus OC patients (p < 0.05). In LC patients, 
31.3% of patients were converted to open surgery. No other differences existed between OC and LC patients 
(p > 0.05).
Propensity-score matched outcomes. The percentage of patients who experienced at least one of the 
adverse postoperative outcomes was 10.7% (95% CI − 16.7; − 4.7) lower in LC versus OC patients (Table 2). 
For every nine patients treated with LC, there was one fewer adverse postoperative outcome compared to OC. 
Prolonged ileus was 11.0% (95% CI − 15.7; − 6.2) lower in LC versus OC patients. The percentage of LC patients 
requiring blood transfusion was 4.3% (95% CI − 8.7; 0.0) lower in LC versus OC patients. Length of stay was 
an average of 2 days (95% CI − 3.1; − 1.1) shorter for LC versus OC patients. However, LC patients were in the 
operating room an average of 14.3 min longer (95% CI 2.2; 26.5). Mortality was similar in both patient groups. 
No other statistical differences existed between OC and LC patients. For all comparisons, LC and OC patients 
were well balanced after matching based on the standardized differences as well as the means and variances of 
the covariates.
Heterogeneity in LC effectiveness. Postoperative outcomes were similar for both LC and OC among 
patients with T4a and those with T4b colon cancer (p = 0.976) (Table 3). There were no significant differences in 
length of stay between both types of surgery among T4a and T4b colon cancer patients (p = 0.989). Mean length 
of operation was longer among T4b patients regardless of the type of surgery, and LC resulted in longer average 
operation time among T4a patients (p = 0.005).
Composite adverse postoperative outcomes between LC and OC were similar regardless of where the tumor 
was located (ascending, descending, transverse colon) (p = 0.397) (Table 4). Mean length of stay was consistently 
lower for LC versus OC patient, but this was irrespective of where the tumor was located (p = 0.930). Mean length 
of operation was lower among tumors located in the ascending colon versus those located in the descending or 
transverse colon. Additionally, the difference in operation time between LC and OC differed by location, with 
LC associated with an increase in operation time for tumors located in the descending colon, a slight reduction 
in operation time for tumors in the transverse and ascending colon (p = 0.001).
The composite outcome, length of stay, and length of operation were all similar between OC and LC among 
obese and nonobese patients (Table 5). While 45.2% of obese patients who underwent OC experienced at least 
one of the composite outcomes compared to 35.5% of obese patients who underwent LC, this same of pattern 
of worse composite outcomes when undergoing OC was seen among nonobese patients. Thus, LC was similarly 
effective compared to OC among obese versus nonobese patients with T4 colon cancer (p = 0.295). Mean length 
of stay was about two days shorter for LC versus OC, but that difference existed for both obese and nonobese 
patients (p = 0.589). The mean length of operation was about 20 min longer in LC versus OC patients, but this 
difference was similar for both obese and nonobese T4 colon cancer patients (p = 0.357).
Our findings were generally robust with respect to different methods of propensity score matching and inclu-
sion of hand-assisted approach in LC (online Tables 1–4).
Discussion
This is the first and largest study to examine differences in effectiveness of LC in various types of locally advanced 
(T4) colon cancer patients. In matched analysis, LC patients had better overall outcomes and shorter lengths 
of stay compared with OC patients. Studies to date comparing LC and OC in T4 colon cancer patients consist 
predominantly of single-institution studies and one meta-analysis of five small studies, resulting in unstable 
estimates of many patient  outcomes13–17.
T4b tumors are technically more demanding than T4a colon tumors. Our results show that LC is less likely to 
be used in T4b than T4a cancers, due to possible involvement of other organs requiring multi-visceral resection. 
We also observed no statistical difference in outcomes using data of over 900 T4a and T4b colon cancer patients, 
suggesting that LC can be used safely in T4b patients. Only two  studies15,26 were identified as part of a recent 
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Patient characteristic Total (n = 1370) Laparoscopic surgery (n = 563) Open surgery (n = 807)
Sex
Male 48 46.7 49
Female 52 53.3 51.1
Age group (years)
< 45 6.5 7.1 6.1
45–54 12.7 13.9 11.9
55–64 21.1 21.5 20.8
65–74 24.4 25 23.9
75 + 35.3 32.5 37.3
Race
White 71.1 70.9 71.3
African American 10.5 9.1 11.5
Other 4.3 1.3 4.3
Unknown 14.1 15.8 12.9
Hispanic ethnicity
No 84 83 84.8
Yes 2.6 3.6 1.9
Unknown 13.4 13.5 13.4
Body mass index*
 ≥ 30 kg/m2 29 33.8 25.7
 < 30 kg/m2 71 66.2 74.3
ASA category*
1 1.8 2.8 1.1
2 33.8 40.7 29
3 56 51.3 59.2
4 8 5 10.2
Unknown 0.4 0.2 0.5
Tumor type*
T4 14.5 14.4 14.6
T4a 53.3 65.2 45
T4b 32.2 20.4 40.4
Current smoker
Yes 17.9 18.1 17.7
No 82.1 81.9 82.3
Preoperative mechanical bowel preparation*
Yes 49.9 56.1 45.6
No 37.5 30.9 42
Unknown 12.6 13 12.4
Cancer location*
Left 36.1 37.8 34.9
Right 43.5 46.2 41.6
Transverse 20.4 16 23.4
AJCC stage*
II 36 31.6 39
III 63.8 68 60.8
Unknown 0.2 0.4 0.1
Chemotherapy w/i 90 days *
Yes 5.8 2.3 8.3
No 93.1 96.5 90.7
Unknown 1.1 1.2 1
Diabetes 16.7 16.3 17
Functional health status 4.3 3 5.1
Chronic kidney disease
0 79.2 77.6 16.6
1 17.1 17.8 80.3
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meta-analysis focused on patient outcomes using LC in T4b colon  cancers18. Neither study observed differences 
in overall survival between the LC and OC groups, but the power to detect clinically important differences was 
low because there were fewer than 100 T4b patients in both studies combined.
LC of transverse colon cancers is more challenging than cancers at other locations in the colon because of 
anatomical  constraints24. Small studies that excluded locally advanced colon cancers showed few differences 
Table 1.  Patient characteristics by laparoscopic versus open surgery, NSQIP 2013–2015. * p < 0.05; Other race 
includes American Indian, Alaskan Native, Native Hawaiian, Pacific Islander, or Asian; CI: confidence interval; 
SD: standard deviation.
Patient characteristic Total (n = 1370) Laparoscopic surgery (n = 563) Open surgery (n = 807)
Anemia*
Unknown 2.6 3 2.2
No anemia 33.9 41.6 28.5
Mild 47.3 42.8 50.4
Moderate 13 11 14.4
Severe 3.3 1.6 4.5
Admission year
2013 26 23.1 28
2014 30.9 32.2 30
2015 43.1 44.8 42
Table 2.  Patient outcomes of laparoscopic versus open colectomy, NSQIP 2013–2015. * p < 0.05 in unadjusted 
LC (laparoscopic colectomy) versus OC (open colectomy) comparison; **Composite outcome includes 
readmission, reoperation, wound infection, blood transfusion, prolonged ileus, sepsis, myocardial infarction, 
deep vein thrombosis, pulmonary embolism, and mortality; SD: standard deviation.
Patient outcome
Total Unmatched analysis Propensity-matched analysis
(n = 1370)
Laparoscopic colectomy 
(n = 563) Open colectomy (n = 807)
Average treatment effect: LC 
versus OC (%)
Total number of patients (1:1 
match)
Postoperative
 Composite outcome (%)** 45.1 35.0* 52.2 − 10.7 (− 16.7; − 4.7) 1106
 Mortality (%) 3.1 1.8* 4.1 − 0.8 (− 0.3; 1.1) 1106
 Readmission (%) 11.1 9.4 12.3 − 3.3 (− 7.3; 0.5) 1104
 Reoperation (%) 5.2 5.3 5.1 0.2 (− 2.6; 3.1) 1106
 Sepsis (%) 6.0 5.0 6.7 − 0.2 (− 3.0; 2.6) 1106
 Prolonged postoperative ileus 
(%) 21.8 14.4* 26.9 -11.0 (-15.7; -6.2) 1104
 Bleeding requiring blood trans-
fusion (%) 18.0 11.9* 22.2 − 4.3 (− 8.7; 0.0) 1106
 Mean length of stay in days 
mean, SD) 9.4 (8.5) 7.6 (8.1)* 10.7 (8.5) − 2.1 (− 3.1; − 1.1) 1106
Peri-operative
 Mean length of operation in 
minutes (SD) 180.2 (99.1) 185.2 (90.8) 176.7 (104.5) 14.3 (2.2; 26.5) 1104
 Anastomotic leak (%) 3.5 3.2 3.7 0.1 (− 2.1; 2.4) 1102
Table 3.  Effect of laparoscopic versus open colectomy by type of T4 tumor, NSQIP 2013–2015. * p < 0.05 
based on propensity score-matched patients comparing T4a versus T4b patients. LC: laparoscopic colectomy; 
OC: Open colectomy; SD: standard deviation. Composite outcome includes readmission, reoperation, wound 
infection, blood transfusion, prolonged ileus, sepsis, myocardial infarction, deep vein thrombosis, pulmonary 
embolism, and mortality.
Patient outcome
T4a patients (n = 675) T4b patients (n = 264)
p*LC OC LC OC
Composite adverse postoperative outcome (%) 110 (30.6%) 142 (45.1%) 53 (46.9%) 80 (53.0%) 0.976
Mean length of stay in days (SD) 7.1 (8.3) 9.9 (9.2) 9.0 (8.0) 10.5 (7.8) 0.989
Mean length of operation in min (SD) 180.1 (87.8) 144.7 (80.5) 209.6 (97.7) 216.8 (123.8) 0.005
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between LC and OC in transverse colon  cancers22–24. Our results extend these findings to suggest that LC can be 
used safely and effectively in locally advanced cancer, even those located in the transverse colon.
Older studies have argued that obesity could be a contra-indication to LC because of technically  difficulties20,21. 
However, our results show that obese patients were more likely to receive LC than nonobese patients during 
2013–2015. While LC appears to result in similar patient outcomes in obese and nonobese colon cancer  patients33, 
T4 colon cancer patients were not included. Small studies with fewer than 50 patients showed similar outcomes 
of LC in obese and nonobese patients who receive colon resection for various  reasons34. Our finding based on 
1370 patients now confirm these results to show similar outcomes of LC in obese and nonobese T4 patients, 
suggesting that there is no reason for obese T4 colon cancer patients not to undergo LC.
A strength of our study is its inclusion of patient outcomes from multiple hospitals reporting on many dif-
ferent types of outcomes. Our matched propensity-score analysis maximized causal  inferences35. High-quality 
observational studies can provide information on treatment effectiveness in  subpopulations36, because it is 
unlikely that a randomized trial will be conducted to determine which patients benefit from LC.
We also recognize some limitations of our findings. Some patient outcomes were relatively infrequent. There-
fore, we constructed a composite outcome, which is less likely to reflect this limitation. In addition, we were 
unable to control for characteristics of hospitals (e.g., enhanced recovery after surgery), surgeons (e.g., volume), 
or tumors (e.g., resection margins, lymph nodes reported) in the propensity score because of confidentiality 
concerns with releasing this data. In addition, the similarity in patient outcomes between LC and OC may be 
due to more skilled laparoscopists at facilities with higher volume. Thus, the potential for selection bias remains 
present. Furthermore, we recognize that the NSQIP typically includes data from larger hospitals and is not a 
nationally representative sample. Finally, we recognize that the effectiveness of LC may vary within the large 
range of BMIs that is included in our definition of obesity (BMI ≥ 30 kg/m2)37, but the sample size was insufficient 
to examine LC effectiveness in patients with BMI ≥ 40 kg/m2.
Thus, T4 colon cancer patients, including obese patients, those with T4b colon cancer, and those with cancer 
located in the transverse colon, can safely receive LC based on their lower rates of adverse outcomes.
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